Stenoparib is under clinical development by Allarity Therapeutics and currently in Phase I for Colon Cancer. According to GlobalData, Phase I drugs for Colon Cancer have a 56% phase transition success ...

This mutation causes embryonic lethality in the homozygous state. To understand the role of Apc in development, we developed homozygous Apc1638N embryonic stem (ES) cell lines. We examined the ...

Despite advancements in cancer treatment technologies, most therapies share a common goal: eliminating cancer cells. However, ...

One’s biological age, which measures the body’s physiological state, may help predict who is at risk for developing colon ...

Ropidoxuridine is under clinical development by Shuttle Pharmaceuticals and currently in Phase I for Colon Cancer.

Uncover how stress and sleep patterns influence cancer risk and learn lifestyle changes that may help reduce colorectal ...

[23] The mechanisms that underlie the protective effect of estrogens on colorectal carcinogenesis are not completely understood, although both direct effects on the ERs expressed in colonocytes ...

Using a computational “digital twin” model, researchers mapped the gene networks controlling cell differentiation. They ...

Estrogens behave as protective agents on the development of colorectal cancer, and hormonal-replacement therapy is associated with an increased survival rate in women with this disease ...

They found that among 100,000 average-risk people who undergo colonoscopy every 10 years, 1,543 would develop colorectal ...

Our gut microbiome — the collection of bacteria, viruses, and fungi in our digestive system — is believed to play a key role ...